Processing

Please wait...

Settings

Settings

Goto Application

1. WO2004024748 - HIGH AFFINITY MONOCLONAL ANTIBODY FOR RECOGNIZING THE PROGESTERONE RECEPTOR (PR) AND METHOD FOR CREATING THE ANTIBODY

Publication Number WO/2004/024748
Publication Date 25.03.2004
International Application No. PCT/US2003/028772
International Filing Date 11.09.2003
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
C07K 16/2869
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2869against hormone receptors
Y10S 435/96
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
435Chemistry: molecular biology and microbiology
96Immunohistochemical assay
Y10S 436/813
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
436Chemistry: analytical and immunological testing
811Test for named disease, body condition or organ function
813Cancer
Applicants
  • SPRING BIOSCIENCE [US]/[US]
Inventors
  • XIA, Haiying
  • HUANG, Zhida
Agents
  • JOHANSEN, Dag
Priority Data
10/242,09211.09.2002US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HIGH AFFINITY MONOCLONAL ANTIBODY FOR RECOGNIZING THE PROGESTERONE RECEPTOR (PR) AND METHOD FOR CREATING THE ANTIBODY
(FR) ANTICORPS MONOCLONAL A HAUTE AFFINITE RECONNAISSANT LE RECEPTEUR DE LA PROGESTERONE (PR) ET METHODE DE MISE AU POINT DE L'ANTICORPS
Abstract
(EN)
A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage compared to currently available PR antibody. Furthermore, the very low background when the lagomorph derived monoclonal antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new PR antibody (clone SP2) antibody had favorable results when compared to mouse monoclonal antibody PR (clone 1A6), the best one in the current market. The PR antibody may prove of great value in the assessment of PR status in human breast cancer. Humanized versions of the PR antibody may provide therapeutic benefits.
(FR)
L'invention concerne un anticorps monoclonal dérivé d'un lagomorphe reconnaissant le récepteur de la progestérone (PR) (clone SP2) par immunohistochimie, et des méthodes de mise au point d'un tel anticorps. L'avantage principal de ces anticorps par rapport aux anticorps PR actuellement disponibles consiste en ce qu'il n'est pas nécessaire de récupérer la cible dans l'immunohistochimie. De plus, le très faible échantillon de contrôle associé à l'anticorps monoclonal dérivé d'un lagomorphe utilisé en immunohistochimie est également sigificatif. L'étude comparative immunohistochimique sur cinquante spécimens cliniques a permis de montrer que le nouvel anticorps PR (clone SP2) offre des résultats favorables comparé à l'anticorps monoclonal murin PR (clone 1A6), le meilleur du marché actuel. L'anticorps PR peut se révéler être d'une grande valeur dans l'évaluation de l'état du PR dans le cancer du sein humain. Les versions humaines de l'anticorps PR peuvent offrir des bienfaits thérapeutiques.
Also published as
Latest bibliographic data on file with the International Bureau